Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Park Place Capital Corp

Park Place Capital Corp grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 365 shares of the pharmaceutical company’s stock after purchasing an additional 36 shares during the quarter. Park Place Capital Corp’s holdings in Vertex Pharmaceuticals were worth $147,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. EverSource Wealth Advisors LLC grew its position in shares of Vertex Pharmaceuticals by 5.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 598 shares of the pharmaceutical company’s stock worth $296,000 after acquiring an additional 33 shares in the last quarter. Public Sector Pension Investment Board boosted its holdings in Vertex Pharmaceuticals by 72.9% in the second quarter. Public Sector Pension Investment Board now owns 9,844 shares of the pharmaceutical company’s stock worth $4,614,000 after purchasing an additional 4,151 shares during the period. Evergreen Capital Management LLC increased its stake in Vertex Pharmaceuticals by 9.1% during the second quarter. Evergreen Capital Management LLC now owns 2,636 shares of the pharmaceutical company’s stock valued at $1,236,000 after purchasing an additional 220 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its holdings in shares of Vertex Pharmaceuticals by 60.3% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 49,474 shares of the pharmaceutical company’s stock worth $23,189,000 after purchasing an additional 18,605 shares during the period. Finally, Sfmg LLC boosted its holdings in shares of Vertex Pharmaceuticals by 0.8% in the 2nd quarter. Sfmg LLC now owns 7,845 shares of the pharmaceutical company’s stock valued at $3,677,000 after buying an additional 60 shares during the period. Institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wells Fargo & Company dropped their price objective on shares of Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. HC Wainwright cut their price target on Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a report on Friday, December 20th. Truist Financial reduced their price objective on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Finally, Barclays reduced their price target on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a report on Friday, December 20th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Trading Up 0.0 %

NASDAQ:VRTX opened at $428.00 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company has a 50-day moving average of $438.10 and a 200-day moving average of $465.39. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the previous year, the business posted $3.67 earnings per share. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.